FI71127C - Foerfarande foer framstaellning av som hjaertlaekemedel anvaendbara 2,2,5,5-tetrametylpyrrolin- och -pyrrolidin-3-karboxylsyraamidderivat - Google Patents
Foerfarande foer framstaellning av som hjaertlaekemedel anvaendbara 2,2,5,5-tetrametylpyrrolin- och -pyrrolidin-3-karboxylsyraamidderivat Download PDFInfo
- Publication number
- FI71127C FI71127C FI843667A FI843667A FI71127C FI 71127 C FI71127 C FI 71127C FI 843667 A FI843667 A FI 843667A FI 843667 A FI843667 A FI 843667A FI 71127 C FI71127 C FI 71127C
- Authority
- FI
- Finland
- Prior art keywords
- group
- general formula
- compounds
- carbon atoms
- derivatives
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 claims description 35
- 150000003839 salts Chemical class 0.000 claims description 13
- 125000004432 carbon atom Chemical group C* 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 7
- 229940079593 drug Drugs 0.000 claims description 7
- 229910052739 hydrogen Inorganic materials 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 7
- 239000001257 hydrogen Substances 0.000 claims description 6
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 5
- 125000000217 alkyl group Chemical group 0.000 claims description 5
- 238000006243 chemical reaction Methods 0.000 claims description 5
- 125000001424 substituent group Chemical group 0.000 claims description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- 150000001412 amines Chemical class 0.000 claims description 4
- 125000001422 pyrrolinyl group Chemical group 0.000 claims description 4
- 125000002947 alkylene group Chemical group 0.000 claims description 3
- 125000003277 amino group Chemical group 0.000 claims description 3
- 150000003857 carboxamides Chemical class 0.000 claims description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 3
- 125000001997 phenyl group Chemical class [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
- 229920006395 saturated elastomer Polymers 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 2
- 125000003545 alkoxy group Chemical group 0.000 claims description 2
- 125000003118 aryl group Chemical group 0.000 claims description 2
- 125000004104 aryloxy group Chemical group 0.000 claims description 2
- 230000000747 cardiac effect Effects 0.000 claims description 2
- 125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- XUWHAWMETYGRKB-UHFFFAOYSA-N piperidin-2-one Chemical class O=C1CCCCN1 XUWHAWMETYGRKB-UHFFFAOYSA-N 0.000 claims description 2
- FMRWQLAJBBKXDM-UHFFFAOYSA-N 2,2,5,5-tetramethylpyrrolidine Chemical compound CC1(C)CCC(C)(C)N1 FMRWQLAJBBKXDM-UHFFFAOYSA-N 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 229910052763 palladium Inorganic materials 0.000 claims 1
- JAEIBKXSIXOLOL-UHFFFAOYSA-N pyrrolidin-1-ium-3-carboxylate Chemical compound OC(=O)C1CCNC1 JAEIBKXSIXOLOL-UHFFFAOYSA-N 0.000 claims 1
- 239000000243 solution Substances 0.000 description 18
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 16
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- UYBWIEGTWASWSR-UHFFFAOYSA-N 1,3-diaminopropan-2-ol Chemical compound NCC(O)CN UYBWIEGTWASWSR-UHFFFAOYSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 206010003119 arrhythmia Diseases 0.000 description 6
- LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 description 6
- XFSBVAOIAHNAPC-XTHSEXKGSA-N 16-Ethyl-1alpha,6alpha,19beta-trimethoxy-4-(methoxymethyl)-aconitane-3alpha,8,10alpha,11,18alpha-pentol, 8-acetate 10-benzoate Chemical compound O([C@H]1[C@]2(O)C[C@H]3[C@@]45C6[C@@H]([C@@]([C@H]31)(OC(C)=O)[C@@H](O)[C@@H]2OC)[C@H](OC)[C@@H]4[C@]([C@@H](C[C@@H]5OC)O)(COC)CN6CC)C(=O)C1=CC=CC=C1 XFSBVAOIAHNAPC-XTHSEXKGSA-N 0.000 description 5
- XFSBVAOIAHNAPC-UHFFFAOYSA-N Aconitin Natural products CCN1CC(C(CC2OC)O)(COC)C3C(OC)C(C(C45)(OC(C)=O)C(O)C6OC)C1C32C4CC6(O)C5OC(=O)C1=CC=CC=C1 XFSBVAOIAHNAPC-UHFFFAOYSA-N 0.000 description 5
- 229940039750 aconitine Drugs 0.000 description 5
- STDXGNLCJACLFY-UHFFFAOYSA-N aconitine Natural products CCN1CC2(COC)C(O)CC(O)C34C5CC6(O)C(OC)C(O)C(OC(=O)C)(C5C6OC(=O)c7ccccc7)C(C(OC)C23)C14 STDXGNLCJACLFY-UHFFFAOYSA-N 0.000 description 5
- 229910000027 potassium carbonate Inorganic materials 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 230000002861 ventricular Effects 0.000 description 5
- 238000010626 work up procedure Methods 0.000 description 5
- 239000003054 catalyst Substances 0.000 description 4
- 230000008602 contraction Effects 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 241000700159 Rattus Species 0.000 description 3
- 230000003288 anthiarrhythmic effect Effects 0.000 description 3
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 3
- 235000019341 magnesium sulphate Nutrition 0.000 description 3
- 229960001404 quinidine Drugs 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 239000003799 water insoluble solvent Substances 0.000 description 3
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical class NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical class Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical class OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 230000007059 acute toxicity Effects 0.000 description 2
- 231100000403 acute toxicity Toxicity 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000006793 arrhythmia Effects 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 238000005984 hydrogenation reaction Methods 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 230000000422 nocturnal effect Effects 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 208000003663 ventricular fibrillation Diseases 0.000 description 2
- VMHVSXXACDJVRL-UHFFFAOYSA-N 3,5-dibromo-2,2,6,6-tetramethylpiperidin-4-one;hydron;bromide Chemical compound Br.CC1(C)NC(C)(C)C(Br)C(=O)C1Br VMHVSXXACDJVRL-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- RJSYPKWVIJGNLO-UHFFFAOYSA-N CCOClOC Chemical compound CCOClOC RJSYPKWVIJGNLO-UHFFFAOYSA-N 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- GEJCIRQLMVVEDX-UHFFFAOYSA-N OOPO Chemical compound OOPO GEJCIRQLMVVEDX-UHFFFAOYSA-N 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 206010047281 Ventricular arrhythmia Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 125000005037 alkyl phenyl group Chemical class 0.000 description 1
- 239000003416 antiarrhythmic agent Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- 125000000950 dibromo group Chemical group Br* 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 230000002828 effect on organs or tissue Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 150000002367 halogens Chemical group 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- NFEIBWMZVIVJLQ-UHFFFAOYSA-N mexiletine hydrochloride Chemical compound [Cl-].CC([NH3+])COC1=C(C)C=CC=C1C NFEIBWMZVIVJLQ-UHFFFAOYSA-N 0.000 description 1
- JUGVRRPKIHNDEF-UHFFFAOYSA-N n-(3-amino-2-hydroxypropyl)-2,2,5,5-tetramethyl-1h-pyrrole-3-carboxamide Chemical compound CC1(C)NC(C)(C)C(C(=O)NCC(O)CN)=C1 JUGVRRPKIHNDEF-UHFFFAOYSA-N 0.000 description 1
- NTWSXJRFFRITSK-UHFFFAOYSA-N n-(3-aminopropyl)-2,2,5,5-tetramethyl-1h-pyrrole-3-carboxamide Chemical compound CC1(C)NC(C)(C)C(C(=O)NCCCN)=C1 NTWSXJRFFRITSK-UHFFFAOYSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- -1 polyethylene Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- REQCZEXYDRLIBE-UHFFFAOYSA-N procainamide Chemical compound CCN(CC)CCNC(=O)C1=CC=C(N)C=C1 REQCZEXYDRLIBE-UHFFFAOYSA-N 0.000 description 1
- 229960000244 procainamide Drugs 0.000 description 1
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical group CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 1
- 150000003236 pyrrolines Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 206010047302 ventricular tachycardia Diseases 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU17883 | 1983-01-20 | ||
| HU83178A HU189214B (en) | 1983-01-20 | 1983-01-20 | Process for preparing pyrroline and pyrrolidine carboxamide derivatives |
| HU8400004 | 1984-01-20 | ||
| PCT/HU1984/000004 WO1984002906A1 (en) | 1983-01-20 | 1984-01-20 | New amino derivatives of 2- adn-(2,2,5,5-tetramethyl-3-pyrrolin-3-carbonyl) bd |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| FI843667L FI843667L (fi) | 1984-09-19 |
| FI843667A0 FI843667A0 (fi) | 1984-09-19 |
| FI71127B FI71127B (fi) | 1986-08-14 |
| FI71127C true FI71127C (fi) | 1986-11-24 |
Family
ID=10948332
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI843667A FI71127C (fi) | 1983-01-20 | 1984-09-19 | Foerfarande foer framstaellning av som hjaertlaekemedel anvaendbara 2,2,5,5-tetrametylpyrrolin- och -pyrrolidin-3-karboxylsyraamidderivat |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US4731376A (en, 2012) |
| EP (1) | EP0134795B1 (en, 2012) |
| JP (1) | JPS60500668A (en, 2012) |
| DE (1) | DE3473443D1 (en, 2012) |
| DK (1) | DK166776B1 (en, 2012) |
| FI (1) | FI71127C (en, 2012) |
| HU (1) | HU189214B (en, 2012) |
| SU (1) | SU1333236A3 (en, 2012) |
| WO (1) | WO1984002906A1 (en, 2012) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1984002907A1 (en) * | 1983-01-21 | 1984-08-02 | Alkaloida Vegyeszeti Gyar | New alkyl diamine derivatives |
| US5047555A (en) * | 1988-12-13 | 1991-09-10 | Tanabe Seiyaku Co., Ltd. | 4-aminophenol derivatives and processes for preparing the same |
| HUP9700392A1 (hu) * | 1997-02-10 | 1999-09-28 | ICN Magyarország Részvénytársaság | Egy vagy két hatóanyagot tartalmazó kardioprotektív hatású gyógyszerkészítmények |
| TWI243162B (en) * | 2000-11-10 | 2005-11-11 | Taisho Pharmaceutical Co Ltd | Cyanopyrrolidine derivatives |
| US6827226B2 (en) * | 2002-12-09 | 2004-12-07 | Wmc Holdings Incorporated | Storage apparatus for sportboards with variable widths |
| HRP20160553T1 (hr) | 2010-08-31 | 2016-09-23 | Bionure Farma, S.L. | Agonisti receptora neurotrofina i njihova uporaba kao lijekova |
| JP6358398B2 (ja) | 2015-09-04 | 2018-07-18 | Dic株式会社 | 液晶組成物及びそれを使用した液晶表示素子 |
| WO2017038552A1 (ja) * | 2015-09-04 | 2017-03-09 | Dic株式会社 | 安定剤化合物、液晶組成物および表示素子 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE109345C (en, 2012) * | ||||
| US3020288A (en) * | 1962-02-06 | Hypotensive compounds | ||
| DE109347C (en, 2012) * | ||||
| DE109346C (en, 2012) * | ||||
| GB190004799A (en) * | 1900-03-13 | 1900-05-19 | George William Johnson | The Manufacture of Para-amidophenyl Glyoxylic Acid, its Substitution Products and Homologues. |
| CH336068A (de) * | 1955-04-06 | 1959-02-15 | Bofors Ab | Verfahren zur Herstellung von Amiden von N-Alkyl-piperidin-monocarbonsäuren oder N-Alkyl-pyrrolidin-a-monocarbonsäuren |
| GB983134A (en) * | 1962-06-13 | 1965-02-10 | American Cyanamid Co | Cyclic nitroxides and process for preparing same |
| US3250771A (en) * | 1962-12-17 | 1966-05-10 | Geigy Chem Corp | 5-monocarbocyclic aryl-n-lower alkyl-2-pyrrolidine carboxylic acid, esters, amides and derivatives thereof |
| US3299097A (en) * | 1963-04-29 | 1967-01-17 | Upjohn Co | 4-alkylhygric acid hydrazides |
| US3313801A (en) * | 1965-10-18 | 1967-04-11 | Upjohn Co | Process for inhibiting n-alkylation of pyrrolidines and substituted pyrrolidines by microorganisms, and products produced thereby |
| US3624081A (en) * | 1967-02-15 | 1971-11-30 | Sterling Drug Inc | 1-acyl-2-ethylidenepyrrol-idine-3-carboxamides |
| US4111901A (en) * | 1977-06-06 | 1978-09-05 | Borg-Warner Corporation | Hindered five-membered nitrogen rings as polyolefin stabilizers |
| US4302383A (en) * | 1980-05-19 | 1981-11-24 | Borg-Warner Chemicals, Inc. | Stabilized olefin polymers |
-
1983
- 1983-01-20 HU HU83178A patent/HU189214B/hu not_active IP Right Cessation
-
1984
- 1984-01-20 JP JP59500631A patent/JPS60500668A/ja active Granted
- 1984-01-20 WO PCT/HU1984/000004 patent/WO1984002906A1/en active IP Right Grant
- 1984-01-20 US US06/898,723 patent/US4731376A/en not_active Expired - Fee Related
- 1984-01-20 DE DE8484900529T patent/DE3473443D1/de not_active Expired
- 1984-01-20 EP EP84900529A patent/EP0134795B1/de not_active Expired
- 1984-09-19 FI FI843667A patent/FI71127C/fi not_active IP Right Cessation
- 1984-09-19 DK DK447284A patent/DK166776B1/da active
- 1984-09-20 SU SU843800100A patent/SU1333236A3/ru active
Also Published As
| Publication number | Publication date |
|---|---|
| FI843667L (fi) | 1984-09-19 |
| DK447284A (da) | 1984-11-20 |
| EP0134795A1 (en) | 1985-03-27 |
| US4731376A (en) | 1988-03-15 |
| EP0134795B1 (de) | 1988-08-17 |
| JPS60500668A (ja) | 1985-05-09 |
| HU189214B (en) | 1986-06-30 |
| JPH0471067B2 (en, 2012) | 1992-11-12 |
| DK166776B1 (da) | 1993-07-12 |
| WO1984002906A1 (en) | 1984-08-02 |
| DK447284D0 (da) | 1984-09-19 |
| SU1333236A3 (ru) | 1987-08-23 |
| FI843667A0 (fi) | 1984-09-19 |
| FI71127B (fi) | 1986-08-14 |
| DE3473443D1 (en) | 1988-09-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI67369B (fi) | Foerfarande foer framstaellning av nya terapeutiskt aktiva derivat av 3,4-dehydroprolin | |
| CN112689629A (zh) | 用于抑制Nav1.8的哒嗪化合物 | |
| KR100241859B1 (ko) | 트라마돌 n-옥사이드 및 그의 에난티오머 및 조성물, 및 이들의 용도 | |
| FI71127B (fi) | Foerfarande foer framstaellning av som hjaertlaekemedel anvaendbara 2,2,5,5-tetrametylpyrrolin- och pyrrolidin-3-karboxylsyraamidderivat | |
| NO129464B (en, 2012) | ||
| KR100352899B1 (ko) | 새로운3-페닐설포닐-3,7-디아자바이사이클로[3,3,1]노난-화합물을함유하는약제 | |
| MXPA02001215A (es) | Derivados sustituidos de pirrolidin-2, 3, 4-trion-3-oxima utiles como antagonistas del receptor nmda. | |
| FI86845B (fi) | Foerfarande foer framstaellning av en terapeutiskt anvaendbar fluorallylamin. | |
| CA1136136A (en) | Triazinones | |
| US3972935A (en) | Antiarrhythmic agents | |
| JP4030578B2 (ja) | 新規の抗痙攣作用を有する４位に二置換アミン基を有する１−アリール（アラルキル）−イミダゾリン−２−オンおよびその製法 | |
| FI61484B (fi) | Foerfarande foer framstaellning av z-3-(4-bromfenyl)-n-metyl-3-(3-pyridyl)-allylamin med antidepressiv och aongestdaempande verkan | |
| KR940011528B1 (ko) | Nn-디메틸에틸아민의 n-옥사이드, 및 이를 함유하는 약제조성물의 제조방법 | |
| SU1384200A3 (ru) | Способ получени бициклических соединений или их аддитивных солей сол ной кислоты | |
| SU1517759A3 (ru) | Способ получени 4-амино-2-(2-бутанон-3-ил)-окси-5-хлор-N-[2-(диэтиламино)этил]бензамида или его солей | |
| KR840001035B1 (ko) | 4-저급알킬-3-페녹시피리딘-1-옥사이드의 제조발법 | |
| US4587360A (en) | Anti-arrhythmic agents | |
| SE465675B (sv) | Basiska oximetrar, foerfarande foer framstaellning daerav och farmaceutiska kompositioner innehaallande desamma | |
| FI57254C (fi) | Analogifoerfarande foer framstaellning av antiarytmiskt aktiva primaera aminoacylanilider | |
| KR890000621B1 (ko) | 불소화된 디아미노알켄 유도체의 제조방법 | |
| US4018897A (en) | Antiarrhythmic agents | |
| Rzeszotarski et al. | Cardioselectivity of. beta.-adrenoceptor blocking agents. 1. 1-[(4-Hydroxyphenethyl) amino]-3-(aryloxy) propan-2-ols | |
| NZ201591A (en) | Fluorinated alkane diamine derivatives | |
| SU1058505A3 (ru) | Способ получени производных индолизина | |
| US4008329A (en) | Substituted cyclohexanes, pharmaceutical compositions containing them and method of treatment involving their use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM | Patent lapsed |
Owner name: ALKALOIDA VEGYéSZETI GYAR |